Table 4.

Multivariate analysis of predictors of risk of therapy discontinuation and substitution

Variable	Simvastatin
	Substitution			Discontinuation
	HR	95% CI	p Value	HR	95% CI	p Value
Age	0.993	0.990 to 0.995	<0.001	1.001	0.999 to 1.004	0.194
Male sex	1.116	1.050 to 1.186	<0.001	0.921	0.882 to 0.963	<0.001
High CVR	1.107	1.034 to 1.185	0.004	0.962	0.914 to 1.013	0.140
Additional CV treatments	1.064	0.984 to 1.152	0.121	0.821	0.778 to 0.867	<0.001
Switch to different product of the same substance	1.059	0.996 to 1.126	0.068	1.087	1.040 to 1.136	<0.001
	Ramipril
	Substitution			Discontinuation
	HR	95% CI	p Value	HR	95% CI	p Value
Age	1.003	1.000 to 1.006	0.072	1.005	1.002 to 1.007	<0.001
Male sex	0.938	0.865 to 1.017	0.119	0.950	0.900 to 1.002	0.058
High CVR	1.158	1.057 to 1.269	0.002	0.866	0.811 to 0.926	<0.001
Additional CV treatments	1.521	1.360 to 1.700	<0.001	0.806	0.757 to 0.857	<0.001
Switch to different product of the same substance	0.973	0.892 to 1.062	0.540	1.163	1.100 to 1.230	<0.001
	Amlodipine
	Substitution			Discontinuation
	HR	95% CI	p Value	HR	95% CI	p Value
Age	1.019	1.013 to 1.024	<0.001	1.006	1.004 to 1.008	<0.001
Male sex	0.807	0.719 to 0.907	<0.001	0.870	0.834 to 0.909	<0.001
High CVR	1.247	1.091 to 1.424	0.001	0.879	0.831 to 0.929	<0.001
Additional CV treatments	1.935	1.514 to 2.474	<0.001	0.959	0.897 to 1.025	0.215
Switch to different product of the same substance	1.179	1.043 to 1.333	0.008	1.124	1.074 to 1.177	<0.001

CV, cardiovascular; CVR, cardiovascular risk.